SELECT TAVR Trial to Compare Myval and Evolut Valves in Borderline Annuli Patients
The SELECT TAVR trial will assess the noninferiority of Myval transcatheter heart valves compared to Evolut valves in patients with borderline annular dimensions.
Asset / Drug
Drug and asset intelligence for Myval with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.